ABOUT THE COMPANY

Regenetech® is initially concentrating its research efforts on development of umbilical cord blood and peripheral blood expansion, increased regeneration of bone for orthopedic uses, and production of biomolecules.
Regenetech®’s business purpose is to commercialize adult stem cell expansion technology by developing stem cell and tissue regeneration technology, patenting it quickly and either licensing or establishing joint ventures to commercialize the technology to generate revenue.

Regenetech® intends to give priority to development of new technology that can be commercialized quickly. Regenetech® will target major pharmaceutical, biotech, and early-stage commercialization companies as potential licensees and/or joint venture partners. Regenetech® believes that its unique ability to be the “first to patent” its new technology gives it a significant presence in the market.